Filing Flows › Protagonist Therapeutics (PTGX) › Q1 2025
Protagonist Therapeutics (PTGX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Protagonist Therapeutics (PTGX) reported revenue of $28.3M for the first quarter 2025 (Q1 2025), -89% from a year earlier and -83% from the quarter before. Operating margin was -68.2%, net loss $11.7M (41.2% of revenue).
Protagonist Therapeutics, Q1 2025: revenue $28.3M (-89% year over year), operating margin -68.2%, net loss $11.7M, operating cash flow $125M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.3M | -83% | -89% |
| Operating profit | −$19.3M | — | — |
| Net earnings | −$11.7M | — | — |
| Operating cash flow | $125M | — | — |
| Free cash flow | $125M | — | — |
What changed
Revenue was $28.3M in Q1 2025, down 89% year over year and down 83% from the previous quarter.
Operating costs exceeded revenue by $19.3M, an operating margin of -68.2%. Total costs fell 2% while revenue fell 89%. The quarter ended with a net loss of $11.7M, after a profit of $131.7M the previous quarter. Non-operating items added $7.7M, -66% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $125.4M. Non-cash charges added back $239K of depreciation and amortization and $13.8M of share-based compensation. Working capital and other items added $123.0M. Capital expenditures of $545K left free cash flow of $124.8M.
Questions
What was Protagonist Therapeutics' revenue in the first quarter 2025?
Protagonist Therapeutics (PTGX) reported revenue of $28.3M for the first quarter 2025 (Q1 2025), -89% from a year earlier and -83% from the quarter before.
Was Protagonist Therapeutics profitable in the first quarter 2025?
Operating loss was $19.3M (-68.2% of revenue) and net loss $11.7M.